
What nearly brainless rodents know about weight loss and hunger
To find out, Grill dripped liquid food into their mouths.
'When they reached a stopping point, they allowed the food to drain out of their mouths,' he said.
Those studies, initiated decades ago, were a starting point for a body of research that has continually surprised scientists and driven home that how full animals feel has nothing to do with consciousness. The work has gained more relevance as scientists puzzle out how exactly the new drugs that cause weight loss, commonly called GLP-1s and including Ozempic, affect the brain's eating-control systems.
The emerging story does not explain why some people get obese and others do not. Instead, it offers clues about what makes us start eating, and when we stop.
While most of the studies were in rodents, it defies belief to think that humans are somehow different, said Dr Jeffrey Friedman, an obesity researcher at Rockefeller University in New York. Humans, he said, are subject to billions of years of evolution leading to elaborate neural pathways that control when to eat and when to stop eating. The second this rodent looks at food, its brain starts assessing how many calories it may have. Photo / Josh Norem, The New York Times
As they have probed how eating is controlled, researchers learned that the brain is steadily getting signals that hint at how calorically dense a food is. There's a certain amount of calories the body needs, and these signals make sure the body gets them.
The process begins before a lab animal takes a single bite. Just the sight of food spurs neurons to anticipate whether a lot of calories will be packed into that food. The neurons respond more strongly to a food like peanut butter – loaded with calories – than to a low-calorie one like mouse chow.
The next control point occurs when the animal tastes the food: neurons calculate the caloric density again from signals sent from the mouth to the brainstem.
Finally, when the food makes its way to the gut, a new set of signals to the brain lets the neurons again ascertain the caloric content.
And it is actually the calorie content that the gut assesses, as Zachary Knight, a neuroscientist at the University of California San Francisco, learned.
He saw this when he directly infused three types of food into the stomachs of mice. One infusion was of fatty food, another of carbohydrates and the third of protein. Each infusion had the same number of calories.
In each case, the message to the brain was the same: The neurons were signalling the amount of energy, in the form of calories, and not the source of the calories.
When the brain determines enough calories were consumed, neurons send a signal to stop eating.
Knight said these discoveries surprised him. He'd always thought that the signal to stop eating would be 'a communication between the gut and the brain,' he said. There would be a sensation of having a full stomach and a deliberate decision to stop eating.
Using that reasoning, some dieters try to drink a big glass of water before a meal, or fill up on low-calorie foods, like celery.
But those tricks have not worked for most people because they don't account for how the brain controls eating. In fact, Knight found that mice do not even send satiety signals to the brain when all they are getting is water.
It is true that people can decide to eat even when they are sated, or can decide not to eat when they are trying to lose weight. And, Grill said, in an intact brain – not just a brainstem – other areas of the brain also exert control.
But, Friedman said, in the end the brain's controls typically override a person's conscious decisions about whether they feel a need to eat. He said, by analogy, you can hold your breath – but only for so long. And you can suppress a cough – but only up to a point.
Scott Sternson, a neuroscientist with the University of California in San Diego and Howard Hughes Medical Institute, agreed.
'There is a very large proportion of appetite control that is automatic,' said Sternson, a co-founder of a startup company, Penguin Bio, that is developing obesity treatments. People can decide to eat or not at a given moment. But, he added, maintaining that sort of control uses a lot of mental resources.
'Eventually, attention goes to other things and the automatic process will wind up dominating,' he said.
As they probed the brain's eating-control systems, researchers were continually surprised.
They learned, for example, about the brain's rapid response to just the sight of food.
Neuroscientists had found in mice a few thousand neurons in the hypothalamus, deep in the brain, that responded to hunger. But how are they regulated? They knew from previous studies that fasting turned these hunger neurons on and that the neurons were less active when an animal was well fed.
Their theory was that the neurons were responding to the body's fat stores. When fat stores were low – as happens when an animal fasts, for example – levels of leptin, a hormone released from fat, also are low. That would turn the hunger neurons on. As an animal eats, its fat stores are replenished, leptin levels go up, and the neurons, it was assumed, would quieten down.
The whole system was thought to respond only slowly to the state of energy storage in the body.
But then three groups of researchers, independently led by Knight, Sternson and Mark Andermann of Beth Israel Deaconess Medical Center, examined the moment-to-moment activity of the hunger neurons.
They began with hungry mice. Their hunger neurons were firing rapidly, a sign the animals needed food.
The surprise happened when the investigators showed the animals food.
'Even before the first bite of food, the activity of those neurons shut off,' Knight said. 'The neurons were making a prediction. The mouse looks at food. The mouse predicts how many calories it will eat.'
The more calorie-rich the food, the more neurons turn off.
'All three labs were shocked,' said Dr Bradford Lowell, who worked with Andermann at Beth Israel Deaconess. 'It was very unexpected.'
Lowell then asked what might happen if he deliberately turned off the hunger neurons even though the mice hadn't had much to eat. Researchers can do this with genetic manipulations that mark neurons so they can turn them on and off with either a drug or with a blue light.
These mice would not eat for hours, even with food right in front of them.
Lowell and Sternson independently did the opposite experiment, turning the neurons on in mice that had just had a huge meal, the mouse equivalent of a Thanksgiving dinner. The animals were reclining, feeling stuffed.
But, said Andermann, who repeated the experiment, when they turned the hunger neurons on, 'The mouse gets up and eats another 10 to 15% of its body weight.' He added, 'The neurons are saying, 'Just focus on food.'' Researchers could switch neurons on and off, and it would affect how much a rodent was willing to eat. Photo / Zachary Knight, Thew New York Times
Researchers continue to be amazed by what they are finding – layers of controls in the brain that ensure eating is rigorously regulated. And hints of new ways to develop drugs to control eating.
One line of evidence was discovered by Amber Alhadeff, a neuroscientist at the Monell Chemical Senses Center and the University of Pennsylvania. She recently found two separate groups of neurons in the brainstem that respond to the GLP-1 obesity drugs.
One group of neurons signalled that the animals have had enough to eat. The other group caused the rodent equivalent of nausea. The current obesity drugs hit both groups of neurons, she reports, which may be a factor in the side effects many feel. She proposes that it might be possible to develop drugs that hit the satiety neurons but not the nausea ones.
Alexander Nectow, of Columbia University, has another surprise discovery. He identified a group of neurons in the brainstem that regulate how big a meal is desired, tracking each bite of food. 'We don't know how they do it,' he said.
'I've been studying this brainstem region for a decade and a half,' Nectow said, 'but when we went and used all of our fancy tools, we found this population of neurons we had never studied.'
He's now asking if the neurons could be targets for a class of weight loss drugs that could upstage the GLP-1s.
'That would be really amazing,' Nectow said.
This article originally appeared in The New York Times.
Written by: Gina Kolata
Photographs by: Josh Norem, Zachary Knight
©2025 THE NEW YORK TIMES
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

1News
2 days ago
- 1News
Weight loss drug Ozempic/Wegovy is days away — all you need to know
Weight loss drug Wegovy, which also goes by the name Ozempic, is responsible for slimming down celebrities such as Oprah Winfrey, threatening the profits of global junk food companies and potentially decreasing obesity rates in the US. New Zealand has watched the impact from a distance – through TikTok, Instagram and news reports – since the drug first entered the US market in 2017 as the diabetes medication Ozempic. Oprah Winfrey (file image). (Source: Bang Showbiz) Its ability to cancel "food noise' and suppress appetite was soon noticed, and in 2021 the drug maker Novo Nordisk remarketed the drug as a weight loss solution under the name Wegovy. Global shortages and a black market ensured. Medsafe approved Ozempic for diabetes in 2023 and Wegovy for weight loss in March 2025 as a prescription medication in conjunction with a reduced-calorie diet and increased exercise. Wegovy's guidelines state that the medication is for those considered obese and with a body mass index (BMI) over 30 or with a BMI of more than 27 and who have at least one weight-related comorbidity, such as type 2 diabetes. It can also be prescribed to adolescents who are considered obese. ADVERTISEMENT While Novo Nordisk hasn't yet made stock available in New Zealand, that is about to change. What is Wegovy and how does it work? Semaglutide medications work by increasing the levels of a hormone called GLP-1. But certain foods eaten in certain ways can do this too. (Source: Wegovy is self-administered by a weekly injection and mirrors our natural hormone GLP-1, which regulates appetite. Users report a feeling of fullness and the squashing of 'food noise', the constant and intrusive thoughts about food. A 2021 clinical trial of semaglutide, the active ingredient in medications like Wegovy, found that participants lost an average of 15% of their body weight in 68 weeks. Claire Murphy, host of the Mamamia women's health podcast Well, has been on Wegovy since March. She was previously on the same drug under the name Ozempic in 2023, but she had to stop when supply was disrupted globally. 'I didn't truly understand what food noise was because I was always existing with it – the constant preoccupation with 'What am I going to have next?' "...It was like peace for the first time when it came to my relationship with food." ADVERTISEMENT The medication has given Murphy breathing space to make better decisions around food and exercise, while reducing joint pain. When the global shortage of Ozempic disrupted her treatment, she regained a small amount of weight but kept most of it off. 'You can't just continue living your life the same way and expect it to miraculously resolve your weight issues.' Wegovy doesn't just impact weight, but health conditions that are connected to it. It reduces the risk of diabetes, cancer and heart attacks while decreasing liver inflammation as well as a host of other benefits. However, for some patients, Wegovy might be a forever drug. Numerous studies show that many who stop taking Wegovy or similar medications regain much of their weight. When will it launch? Researchers looked at semaglutide, a prescription drug that decreases appetite and is sold under the brand names Wegovy and Ozempic. (Source: 1News) Novo Nordisk would not confirm a New Zealand launch date. However, numerous health professionals confirmed to RNZ that they had been told July 1. ADVERTISEMENT Clive Cannons, from Clive's Chemist in Wainuiomata near Wellington, says his drug wholesaler has listed Wegovy's availability date as July 1. A Novo Nordisk representative recently visited his pharmacy with information on the drug, which is standard procedure ahead of a new drug coming on the market. Representatives are also 'detailing' GPs around New Zealand on best practices for prescribing Wegovy, Cannons said. Dr Lara Courtenay, a weight loss physician at the MacMurray Centre in Auckland was told Wegovy would be available July 1 by a pharmacy wholesaler. She is preparing many of her patients who are on Saxenda, a similar but less effective weight loss drug currently available in New Zealand, to transition to Wegovy from July. Dr Gerard McQuinlan, a Wellington-based GP who specialises in medical weight loss, has told patients he will begin prescribing Wegovy from July 2 to be sure the drug will be available on pharmacists' shelves. 'The patients are hanging out for it because they have all read about it,' said McQuinlan. What will it cost? While Medsafe approved the drug, PHARMAC is currently not funding it so users will pay out of pocket and the cost is high and ongoing. Cannons estimates Wegovy will cost users between $450 to $600 a month. It will be determined by the wholesale price and the price structure of individual pharmacies, he said. ADVERTISEMENT Courtenay believes the price will be around $500 a month, similar to the AU$460 Australians typically pay per month. The slightly higher price for New Zealanders will take into account the exchange rate and the addition of GST, which Australia does not add to medications, she said. What are the side effects? Like most drugs, Wegovy comes with a long list of side effects. Some are common, others are not. Nausea is a highly reported side effect. Murphy experiences this on and off. 'For me, I take a good drink of water, it can go away but for other people I've heard it can be quite bad.' Diarrhea following meals happens occasionally. 'That is something I have had to manage but it is something that is not pleasant,' said Murphy. Wegovy can't be taken with some blood thinning and diabetes medication, said Cannons. Women who are pregnant or are thinking of becoming pregnant should not take Wegovy as animal studies have linked the drug type to birth defects. ADVERTISEMENT 'Young women who want to lose weight, that's something they actually need to consider quite carefully,' he said. The UK's medicines regulator has also warned women that weight loss medications might blunt the effectiveness of oral birth control, potentially resulting in unplanned pregnancies. Regardless of those warnings, Courtenay always recommends patients use barrier protection like a condom while on weight loss medication. 'I have had patients fall pregnant accidentally because women get ultra fertile when they lose weight.' By Serena Solomon for


NZ Herald
3 days ago
- NZ Herald
Weight loss drug Ozempic/Wegovy is days away for NZ. Everything you need to know
Weight loss drug Wegovy, which also goes by the name Ozempic, is responsible for slimming down celebrities such as Oprah Winfrey, threatening the profits of global junk food companies and potentially decreasing obesity rates in the US. New Zealand has watched the impact from a


NZ Herald
17-06-2025
- NZ Herald
How to tackle your to-do list if you struggle with executive functioning
Certain strategies can help you understand and manage executive functoning. Illustration / Cristina Spano, The New York Times Conditions like ADHD and autism can make starting and completing tasks feel impossible, but experts say there are workarounds. The Pomodoro Technique. Power poses. Planners. Denise Daskal has tried them all, searching for the right strategy to improve her executive functioning, or the mental skills used to manage time and